251 286 - Biotech Bayern

Astellas Pharma GmbH
PHARMA & CHEMICAL INDUSTRY
Keywords: Drug Development, Antibiotics, Allergy, Autoimmune Diseases, Immune
Therapy, Infectious Diseases, Inflammation
Astellas Pharma Inc. was formed in April 2005 from a merger with Yamanouchi
and Fujisawa. Astellas Pharma is Japan’s second largest pharmaceutical
company and is headquartered in Tokio. It has operations in Europe, Asia, North
America and Japan. Astellas is focused on four key therapy areas:
Transplantation, urology, dermatology, and anti-infectives.
Astellas employs approximately 3,000 people in Europe across Sales and
Marketing, Research & Development and Manufacturing. Astellas has 19 Sales
and Marketing Affiliates, 3 plants and 1 R&D site in Europe. Astellas Europe is
headquartered just outside London in Staines. The German headquarters are
based in Munich. Located here are Sales, Marketing and Medical. The product
portfolio includes therapies in transplantation, urology, dermatology, asthma/
COPD, cardiology, antibiotics and gastroenterology.
Astellas Pharma GmbH Munich employs approximately 350 people including
225 sales representatives.
Aurigon Life Science GmbH
BIOTECH PRECLINICAL SERVICES
Keywords: Drug Development, Pharmacology, Toxicology
Aurigon Life Science is an independent contract research organization (CRO) which
perfoms preclinical research and development. The main emphasis of the company
is the combination of pharmacological studies and toxicological testing in accordance
with international and national requirements (BfArM, EMEA, FDA, ICH, OECD,
GLP). Aurigon offers an integrated service from strategic planning of the preclincal
development continuing with the pharmacological characterisation and toxicological
testing of the sponsors substance up to the preparation of expert reports
for the legal authorities. This includes a comprehensive range of in house services
in the fields of preclinical efficacy and safety testing for biotechnology and
pharmaceutical companies and the chemical industry.
AVONTEC GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS
Keywords: Drug Development, Respiratory Diseases, Inflammation, Dermatology
AVONTEC GmbH is a Munich-based biopharmaceutical company engaged in the
development of a novel class of nucleic-acid-based anti-inflammatory drugs.
These drugs, based on oligonucleotides that act as decoys for certain transcription
factors, are all directed against biologically validated targets in major chronic
diseases with high unmet medical need. AVONTEC focuses its technology on
chronic inflammatory diseases of the respiratory system and skin. The company has
two products in clinical phase II development.
Contact:
Dr. Martin Marhoefer
Berg-am-Laim-Str. 129
D-81673 München
Phone: +49 (0) 89 4544-1440
Fax: +49 (0) 89 4544-1600
E-Mail: martin.marhoefer@de.astellas.com
Internet: www.astellas.de
Contact:
Dr. Gundel Hager
Bahnhofstr. 9-15, Gebäude 214
D-82327 Tutzing
Phone: +49 (0) 8158 2597-30
Fax: +49 (0) 8158 2597-31
E-Mail: info@aurigon.de
Internet: www.aurigon.de
Contact:
Dr. Thomas Schulze
Fraunhoferstr. 15
D-82152 Martinsried
Phone: +49 (0) 89 8565 1600
Fax: +49 (0) 89 8565 1620
E-Mail: info@avontec.de
Internet: www.avontec.de
43